Celltrion's ZYMFENTRA® Shows Efficacy in Diverse Crohn's Disease Cases: New Insights from LIBERTY-CD Analysis Celltrion reveals compelling results from the LIBERTY-CD post-hoc analysis, demonstrating ZYMFENTRA's consistent efficacy across Crohn's disease sites. Read more!

Celltrion's ZYMFENTRA® Shows Efficacy in Diverse Crohn's Disease Cases: New Insights from LIBERTY-CD Analysis #South_Korea #Crohn's_Disease #Incheon #Celltrion #ZYMFENTRA

Celltrion Unveils Six Abstracts on IBD at 2025 Digestive Disease Week, Enhancing Clinical Insights At the 2025 DDW in San Diego, Celltrion will present six studies on IBD, focusing on ZYMFENTRA's effectiveness for Crohn's and ulcerative colitis.

Celltrion Unveils Six Abstracts on IBD at 2025 Digestive Disease Week, Enhancing Clinical Insights #South_Korea #Inflammatory_Bowel_Disease #Incheon #Celltrion #ZYMFENTRA

Ulcerative colitis drug Zymfentra to generate fifth of Celltrion's 2025 revenue Celltrion plans to generate 20 percent of its annual revenue this year from its original drug Zymfentra as part of its broader strategy to expand into the original drug market.

#Celltrion, a Korean biotech company known for its biosimilars, plans to generate 20 percent of its annual revenue this year from its original drug #Zymfentra as part of its broader strategy to expand into the original drug market.